Broad application across solid tumor types and disease stages.
Most cancer therapies work best when the tumor has high numbers of activated immune cells.
The transplant rejection immune response is 1000x stronger than the immune response to flu or COVID
Localized delivery of AIM-001 during biopsy or tumor resection surgery.
Improve outcomes for patients with advanced solid tumors and limited therapeutic options. Help checkpoint immunotherapy portfolios work better for more patients. Majority of patients do not respond to checkpoint immunotherapy – AIM-001 unlocks the potential.
AIM-001 is simple, localized cell-based therapy implanted at the primary or metastatic tumor site during biopsy or resection surgery. AIM-001 baits the immune system locally and activates the immune system systemically to sensitize patients to checkpoint immunotherapy, resulting in increased response rates, durability, and expanded patient eligibility.
